Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Executive Decisions Roundup

This article was originally published in The Tan Sheet

Executive Summary

POM Wonderful pomegranate dietary supplement marketer The Wonderful Co. is represented in the Aspen Institute’s inaugural “Health Innovators” program; nutritional and sports supplement brands EXOS and MusclePharm and eye care brand EyePromise sign pro athletes; and more news in brief.

You may also be interested in...



Industry Roundup: No GRAS For PHOs, Pfizer Expands In China, MusclePharm Targets Over-40 Consumers

Partially hydrogenated oils lose GRAS; Pfizer expands consumer product output in China; MusclePharm adding direct sales; U.K. requires registration, logo for online sales; and more news in brief.

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107786

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel